Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A pill that works across all stages of menopause? Orforglipron, an oral GLP-1 receptor agonist, helped women with obesity or overweight shed significantly more weight than placebo — whether they were pre-, peri-, or postmenopausal. In one trial, over 80% of women on the drug lost at least 5% of their body weight, compared to just 20–25% on placebo.
A new post hoc analysis of two major clinical trials suggests that orforglipron — an oral, non-peptide GLP-1 receptor agonist made by Eli Lilly — delivers consistent and meaningful weight loss in women with obesity or overweight, regardless of where they are in the menopausal transition. The findings were presented at the EASD 2026 Annual Meeting in Milan.
The analysis drew from ATTAIN-1 (women without diabetes) and ATTAIN-2 (women with type 2 diabetes), splitting female participants into premenopausal, perimenopausal, and postmenopausal subgroups. At week 72, women on the 36 mg dose of orforglipron saw double-digit percentage weight loss across all menopausal stages in both trials — far outpacing placebo results.
By the Numbers:
Why it matters: Menopause is often associated with weight gain and metabolic shifts that make obesity harder to manage. An oral GLP-1 option that works consistently across menopausal stages could be a meaningful addition to the toolkit for clinicians treating women's metabolic health.
